Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9469.121 | 1.0024 | 1.0042 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9469.121 | 0.9588 | 0.9269 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9469.121 | 0.9946 | 0.9904 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9469.121 | 0.9402 | 0.8938 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9469.121 | 0.4221 | -0.0680 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9469.121 | 0.1014 | -0.7361 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9469.121 | 0.1166 | -0.7014 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9469.121 | 0.0788 | -0.7889 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 9469.121 | 0.0033 | -0.9874 | 1.1298 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 10268.007 | 1.0228 | 1.0342 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 10268.007 | 0.9450 | 0.9168 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 10268.007 | 0.6748 | 0.4881 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 10268.007 | 0.5684 | 0.3081 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 10268.007 | 0.0986 | -0.6494 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 10268.007 | 0.0853 | -0.6856 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 10268.007 | 0.0620 | -0.7524 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 10268.007 | 0.0285 | -0.8620 | 1.3306 | |
| HCC38 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10268.007 | 0.0297 | -0.8575 | 1.3306 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7860.043 | 1.0328 | 1.0881 | 0.7488 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7860.043 | 1.0131 | 1.0352 | 0.7488 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7860.043 | 1.0286 | 1.0768 | 0.7488 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7860.043 | 1.0880 | 1.2385 | 0.7488 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7860.043 | 0.8870 | 0.7041 | 0.7488 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7860.043 | 0.9627 | 0.9010 | 0.7488 | |
| HCC70 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7860.043 | 0.8659 | 0.6500 | 0.7488 |